{"id":525776,"date":"2021-08-10T07:03:28","date_gmt":"2021-08-10T11:03:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/"},"modified":"2021-08-10T07:03:28","modified_gmt":"2021-08-10T11:03:28","slug":"gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/","title":{"rendered":"Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference"},"content":{"rendered":"

<\/p>\n

Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference<\/b><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–
\nGemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the H.C. Wainwright Ophthalmology Conference on Tuesday, August 17 at 9:00 AM ET.\n<\/p>\n

\nA live webcast of the event will be available on the “Events & Presentations” page on the Company’s website. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.\n<\/p>\n

About Gemini Therapeutics<\/b><\/p>\n

\nGemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Gemini\u2019s lead candidate, GEM103, is a recombinant form of human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant and a Phase 1\/2a study in patients with neovascular age-related macular degeneration with or at risk for macular atrophy. Gemini has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies and is advancing a potentiating antibody for CFH, GEM307, into clinical development for treatment of systemic diseases.\n<\/p>\n

\nFor more information, visit www.geminitherapeutics.com<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210810005122\/en\/<\/a><\/span><\/p>\n

Gemini Investor:
\n<\/b>
Argot Partners
\n
Sherri Spear
\n
212-600-1902
\n
gemini@argotpartners.com <\/a><\/p>\n

Gemini Media:
\n<\/b>
Argot Partners
\n
Joshua Mansbach
\n
212-600-1902
\n
gemini@argotpartners.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology General Health Health Pharmaceutical Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)– Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the H.C. Wainwright Ophthalmology Conference on Tuesday, August 17 at 9:00 AM ET. A live webcast of the event will be available on the “Events & Presentations” page on the Company’s website. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation. About Gemini Therapeutics Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically … <\/p>\n

Continue reading “Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-525776","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)– Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the H.C. Wainwright Ophthalmology Conference on Tuesday, August 17 at 9:00 AM ET. A live webcast of the event will be available on the “Events & Presentations” page on the Company’s website. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation. About Gemini Therapeutics Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically … Continue reading "Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-10T11:03:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210810005122r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference\",\"datePublished\":\"2021-08-10T11:03:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\\\/\"},\"wordCount\":295,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210810005122r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\\\/\",\"name\":\"Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210810005122r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-08-10T11:03:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210810005122r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210810005122r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/","og_locale":"en_US","og_type":"article","og_title":"Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference - Market Newsdesk","og_description":"Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference CAMBRIDGE, Mass.–(BUSINESS WIRE)– Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the H.C. Wainwright Ophthalmology Conference on Tuesday, August 17 at 9:00 AM ET. A live webcast of the event will be available on the “Events & Presentations” page on the Company’s website. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation. About Gemini Therapeutics Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically … Continue reading \"Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-10T11:03:28+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210810005122r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference","datePublished":"2021-08-10T11:03:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/"},"wordCount":295,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210810005122r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/","name":"Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210810005122r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-08-10T11:03:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210810005122r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210810005122r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gemini-therapeutics-to-participate-in-the-h-c-wainwright-ophthalmology-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=525776"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525776\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=525776"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=525776"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=525776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}